Trial Profile

A clinical study of ABCL-635.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABCL 635 (Primary)
Indications Hot flashes; Vasomotor symptoms
Focus Adverse reactions

Most Recent Events

14 May 2025 According to Abcellera media release, company has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, and the study is anticipated to begin in Q3 of 2025
26 Aug 2024 New trial record
06 Aug 2024 According to Abcellera media release, Clinical Trial Application (CTA) for this clinical trial is anticipated in the second quarter of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com